Printer Friendly

Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation.

1. Introduction

For patients with hematologic malignancies, allogeneic stem cell transplantation (allo-SCT) is a kind of curative treatment [1-3]. Recently, haploidentical SCT provides alternative treatment options for patients lacking human-leukocyte antigen-(HLA-) matched related or unrelated donors. However, prolonged isolated thrombocytopenia (PT), which is defined as the engraftment of all peripheral blood cell lines other than a platelet (PLT) count [greater than or equal to] 20 x [10.sup.9]/L or dependence on PLT transfusions for more than 90 days after allo-SCT, has a great impact on transplant outcomes, especially in haploidentical SCT settings. The incidence of PT is around 5 to 37% after transplantation [4-6]. In our center, we established an unmanipulated haploidentical blood and marrow transplantation (HBMT) protocol that has a lower incidence of graft failure compared to other haploidentical transplant modalities [7], but PT still significantly increases the risk of transplant-related mortality (TRM) [4-6, 8]. Although the impaired PLT production and accelerated peripheral destruction are known to be the major causes of PT [4-6], there still might be other undiscovered factors that remain to be clarified [9].

Donor-specific antibodies (DSAs) are the anti-human leukocyte antigen (HLA) antibodies that specifically respond to the mismatched antigen of donor [10-12]. Several researchers, including us, have confirmed the effects of DSAs on graft failure (GF), including graft rejection (GR) and poor graft function (PGF), in patients who underwent haploidentical SCT either with T cell depletion or with T cell replete [13-15]. However, there is no data on the relationship of DSAs with PT after haploidentical SCT. Here, we performed a retrospective analysis to investigate the association of DSAs with the occurrence of PT in patients who underwent unmanipulated HBMT.

2. Materials and Methods

2.1. Patients. The consecutive patients who received unmanipulated HBMT from March 2010 to March 2014 at Peking University Institute of Hematology were enrolled in this study. All cases underwent DSA examination and had the complete data of DSA before transplantation. The transplant protocol was approved by the Institutional Review Board of Peking University People's Hospital, and the IRB approval number is 2012-27. The clinical trial registration number is NCT01617473. All patients signed informed consent forms. This study was conducted in accordance with the Declaration of Helsinki. The characteristics of patients and donors were shown in Table 1.

2.2. Transplant Protocol. The unmanipulated HBMT was performed as previously described [16, 17]. Patients were conditioned with busulfan (BU, 0.8mg/kg iv, q6h), cyclophosphamide (CTX, 1.8 g/[m.sup.2]/d for 2 days), and antithymocyte globulin (rabbit ATG, Sang Stat, Lyon, France) (2.5 mg/kg/d iv for 4 days) or total body irradiation (TBI, 7.7 Gy), CTX, and ATG. All patients received G-CSF-mobilized bone marrow (BM) and peripheral blood stem cell transfusion. Cyclosporine A, mycophenolate mofetil, and short-term methotrexate were used for prophylaxis of graft-versushost disease (GVHD).

2.3. Anti-HLA Antibody and DSA Examination. The patients and donors underwent HLA allele typing of at least the A, B, and DRB1 loci routinely. The examination was performed as previously [15]. In brief, patient plasma/serum was screened for class I and class II HLA antibodies with a LABScreen Mixed Kit (One Lambda, Canoga Park, CA, USA). The samples were incubated with mixed HLA class I- and class II-coated microspheres for 30 min in the dark and then washed before being incubated with anti-human immunoglobulin G-conjugated fluorescein isothiocyanate as described above for the first incubation. Finally, the samples were examined by a Luminex 200 flow analyzer (Luminex, Austin, TX, USA), and the data were analyzed with the HLA Fusion 3.2 software (One Lambda). The MFI of anti-HLA antibodies was obtained using the formula: sample beads--negative control beads. The samples with a MFI > 500 were further tested for the specificity of the antibody (DSA), using a LABScreen Single Antigen Kit (One Lambda).

2.4. Definitions of Engraftment. Neutrophil engraftment was defined as achieving an ANC more than 0.5 x [10.sup.9]/L for three consecutive days, and platelet recovery was defined as achieving a platelet count more than 20 x [10.sup.9]/L without platelet transfusions for seven consecutive days. Chimerism analysis was performed by DNA fingerprinting for short-tandem repeats in blood samples and/or chromosome fluorescence in situ hybridization of BM samples [18]. Full donor chimerism was defined as [greater than or equal to] 95% leukocytes of donor origin in peripheral blood samples. Mixed chimerism was defined as more than 5% but less than 95% leukocytes of donor origin.

Primary GF consists of GR and PGF. GR is the failure to engraft neutrophils by day +28 for three consecutive days and the absence of donor hematopoiesis. PGF was defined as the presence of three cytopenic counts (ANC [less than or equal to]0.5 x [10.sup.9]/L, platelet [less than or equal to] 20 x [10.sup.9]/L, and hemoglobin (HGB) [less than or equal to]80g/L) beyond day +28 with a complete donor chimerism in the absence of severe GVHD or hematological relapse. PT was defined as the engraftment of all peripheral blood cell lines other than a PLT count [greater than or equal to] 20 x [10.sup.9]/L or dependence on PLT transfusions for more than 90 days after allo-HSCT in the presence of complete donor chimerism. Patients with evidence of PGF or hematologic relapse within 90 days after transplantation were excluded.

2.5. Statistical Analysis. The reference date of June 30th, 2016, was used to define the end of follow-up. The median follow-up was 796 (range: 25-2309) days. The Fisher exact test or Wilcoxon test was used for two-group comparisons. Disease-free survival (DFS), TRM, and overall survival (OS) were calculated according to Kaplan-Meier statistics. Death before +90 d, GR, and PGF were considered a competing risk for PT. The difference of PT between groups was tested according to Gray's method, using R software for statistical computing. A two-sided P value of 0.05 was considered significant. The log-rank test was used for comparisons of Kaplan-Meier curves. Potential prognostic factors for PT, OS, DFS, relapse, and TRM were examined using Cox proportional hazards models. SPSS 22.0 software was used (Mathsoft, Seattle, WA, USA) for statistical analysis.

3. Results

3.1. The General Clinical Characteristics of Patients. Total of 394 patients were enrolled in this study. The median age of patients was 26 years (range, 2-58 years). All patients received a myeloablative conditioning regimen. The median dose of infused [CD34.sup.+] cells was 2.61 (0.39-16.82) x [10.sup.6]/kg. Except for patient age (P = 0.020), cases with PT and those without PT had equivalent patient and donor characteristics (Table 1).

3.2. Engraftment. Three hundred ninety patients achieved myeloid engraftment except for 4 patients (1.0%). The median time to neutrophil engraftment was 13 days (range, 8-27 days). Up to the follow-up, the incidence of platelet engraftment was 91.9% and the median time to platelet engraftment was 17 days (range, 6-265 days). 32 patients did not meet the criteria of platelet engraftment. Total of 4 patients developed GR and 39 patients (9.9%) were PGF. Among the patients who met the criteria of PGF, 9 patients died before +90 days and 16 patients later met the criteria of PT. In patients who met the criteria of PT, 16 patients only met the criteria of PT but not PGF. Thus, the cumulative incidence of PT in this cohort of patients was 9.9 [+ or -] 1.5%.

3.3. HLA Antibodies and DSA. Among all the patients, there were 99 (25.1%) with positive anti-HLA antibody, consisted of 48 males and 51 females. Of these positive patients, 63 (16.0%) had antibodies against HLA class I antigens and 57 (14.5%) had antibodies against HLA class II antigens. 31 (7.9%) patients had HLA antibodies against both classes I and II. In all HLA antibody positive patients, 45 (45.5%) had positive DSA. Of the 394 cases tested, 45 (11.4%) were DSA positive. Because we previously showed that high antibody titers of DSAs (MFI [greater than or equal to] 10,000) were correlated to primary GR (P < 0.001) and that low antibody titers of DSAs (MFI [greater than or equal to] 2000) were strongly associated with primary PGF (P = 0.005) [15], here, we analyzed the impacts of DSAs (MFI [greater than or equal to] 1000) and DSAs (MFI [greater than or equal to] 2000) on PT. Of the DSA positive patients, the MFI of 37 (9.4%) patients were more than 1000 and the MFI of 31 (7.9%) patients were more than 2000. The detailed information about HLA antibodies and DSA was shown in Table 2.

3.4. Relationship of DSAs with PT after Unmanipulated HBMT. The percentages of cases with positive anti-HLA antibody were 9.2% (27/295) in patients with good engraftment, 18.8% (6/32) in patients with PT, 30.8% (12/39) in patients with PGF, and 100% in patients with GR (Table 2). By using a competing risk analysis, the incidence of PT was higher in patient with a MFI [greater than or equal to] 1000 compared with those with a MFI < 1000 (16.8 [+ or -] 6.4% versus 7.4 [+ or -] 1.4%, P = 0.05). For the competing events including death before +90 d, GR, and PGF, the incidence of PT was higher in patients with a MFI [greater than or equal to] 1000 compared with those with a MFI < 1000 (29.9 [+ or -] 7.7% versus 6.5 [+ or -] 1.3%, P <0.001). Univariate analysis showed that factors including elder (P = 0.020), infused lower dose of [CD34.sup.+] cells (P = 0.061), positive HLA antibody (P = 0.092), and HLA class II antibody (P = 0.056) and DSAs (MFI [greater than or equal to] 1000, P = 0.058) were associated with PT after unmanipulated HBMT (Table 3). However, multivariate analysis showed that the presence of DSAs (MFI > 1000) (hazard ratio (HR) 3.262; 95% confidence interval (CI), 1.339-7.946; P = 0.009) was independently associated with PT. It also seemed that an infused lower dose of [CD34.sup.+] cells might predict a higher incidence of PT (HR 0.481; 95% CI, 0.2321.001; P = 0.05, Table 4).

3.5. Relationship of DSAs with Transplant Outcomes. To further investigate the relationship of DSAs with other transplant outcomes including TRM, relapse, DFS, and OS, we also took the above factors into the univariate and multivariate analyses. In the univariate analysis, DSAs (MFI [greater than or equal to] 1000, P = 0.076), grade II-IV acute GVHD (P = 0.033), infused [CD4.sup.+] (P = 0.024) and CD3+ cells (P = 0.088), donor-recipient relationship (P = 0.097), and disease status at the transplantation (P = 0.029) were associated with TRM. The results of multivariate analysis showed that an infused higher dose of [CD4.sup.+] cells and DSAs (MFI [greater than or equal to] 1000) were the independent risk factors of TRM (Table 4). For relapse, disease status (P < 0.001), sex match (P = 0.09), and HLA-DP (P = 0.024) were brought into multivariate analysis. Finally, patients in high risk and HLA-DP were related to leukemia relapse (Table 4). For DFS, chronic GVHD (P = 0.011), disease status (P < 0.001), and sex match (P = 0.094) were conducted into multivariate analysis. As our expected, patients in high risk and with chronic GVHD were associated with DFS (Table 4). It showed that with chronic GVHD (P = 0.006), disease status (P < 0.001) and DSAs (MFI [greater than or equal to] 1000, P = 0.09) were related to OS in univariate and multivariate analyses though DSAs (MFI [greater than or equal to] 1000) did not show a statistical significance (Table 4).

3.6. Effects of PT on Transplant Outcomes. Compared to cases with PT, patients without PT had lower incidence of TRM (16.3 [+ or -] 0.02% versus 32.5 [+ or -] 0.09%, P = 0.043), similar incidence of relapse (12.3 [+ or -] 0.02% versus 14.4 [+ or -] 0.07%, P = 0.677), and higher probabilities of DFS (74.7 [+ or -] 0.02% versus 56.3 [+ or -] 0.88%, P = 0.046) and OS (75.2 [+ or -] 0.02% versus 56.3 [+ or -] 0.88%, P = 0.047) (Figure 1). Multivariate analysis showed that the onset of PT was independently associated with TRM (HR, 2.717; 95% CI, 1.343-5.498; P = 0.005). Besides, patients with PT seemed also to have a worse DFS (HR, 1.695; 95% CI, 0.984-2.921; P = 0.057) and OS (HR, 1.629; 95% CI, 0.928-2.858; P = 0.089).

4. Discussion

The association of DSAs with graft failure has been demonstrated by other researchers and us in either HLA-matched unrelated donor transplant, umbilical cord blood transplantation, or haploidentical transplantation [10-12, 15, 19]. In this study, we, for the first time, found an association of the presence of DSAs with PT after unmanipulated HBMT, indicating that DSAs may be involved in the pathogenesis of this complication. In addition, patients with the onset of PT-experienced inferior transplant outcomes provide further evidence suggesting that the presence of DSAs should be incorporated in the donor selection algorithm [20, 21].

The definition of a threshold for DSAs, according to MFI, is a premise for analyzing the association of DSAs with PT after transplantation. In previous studies, several cutoff values, such as MFI >500, 1000, 1500, 2000, and 5000, have been defined as DSA positive that was associated with graft failure in different transplant modalities with different conditioning-regimens and GVHD prophylaxis [10,11,14,15,22]. In this study, the cutoff value of DSA MFI was 1000, which was associated with the onset of PT after unmanipulated HBMT. Our previous observation indicated that patients with DSA MFI [greater than or equal to] 10000 experienced graft rejection and cases with DSA MFI [greater than or equal to] 2000 experienced PGF. Our results suggest that high, intermediate, and low antibody titers of DSAs may lead to GR, PGF, and PT, respectively [15]. The fact that patients with PT experienced higher cumulative incidence of TRM and inferior DFS and OS supports the logical theory that the presence of DSAs results in PT, which may contribute to inferior survival.

Barge et al. [23] have found that DSAs may kill donor cells through antibody-dependent cell-mediated cytotoxicity (ADCC). In vitro experiment performed by us showed that DSAs could induce apoptosis of [CD34.sup.+] cells and endothelial progenitor cells (EPCs) in the allografts (unpublished data). Kong et al. [24] from our center reported that the PT patients exhibited remarkable decreases in cellular elements of the vascular microenvironment of the bone marrow, including EPCs and perivascular cells, compared to the cases with good graft function after transplantation and the healthy donors, respectively. A multivariate analysis revealed that EPCs were an independent risk factor for PT. Their data suggested that an impaired BM vascular microenvironment may contribute to the occurrence of PT after allo-SCT [24]. It is reasonable that DSAs may lead to BM vascular microenvironment impairment via inducing apoptosis of EPCs, although further studies are needed. Our group also demonstrated that the recruitment of [CD8.sup.+] T cells into BM might explain the suppression of megakaryocyte apoptosis through the elevated expression of [CX3CR1.sup.+] in PT after allo-SCT [25]. These results indicate that an immune-mediated mechanism may contribute to the pathogenesis of PT after unmanipulated HBMT.

The present study had several limitations. First, our study is a single-center retrospective study. A prospective study with a training group and validation group is needed. Second, the present study only investigated the unmanipulated HBMT modality with an ATG conditioning regimen. Therefore, our results should be further confirmed in a multicenter clinical trial and in T cell-depleted haploidentical SCT modalities or in T cell-replete haploidentical SCT settings with postcyclophosphamide [26].

In conclusion, our results not only, for the first time, suggested an association of DSAs with PT after unmanipulated HBMT but also confirmed the effects of PT on inferior transplant outcomes. In addition, our study is clinically relevant and provides further evidence that DSAs should be incorporated in the algorithm for unmanipulated HBMT.

Conflicts of Interest

The authors declare no competing financial interests.

Authors' Contributions

Yingjun Chang designed the study. Yingjun Chang and Xiaosu Zhao collected the data. Yingjun Chang and Xiaosu Zhao analyzed the data and wrote the manuscript. All authors contributed to the interpretation of the data, preparation of the manuscript, and approval of the final version.


The authors thank all the faculty members who participated in this study. This work was supported by the Milstein Medical Asian American Partnership Foundation, the Key Program of National Natural Science Foundation of China (81230013), the National Natural Science Foundation of China (81670175), the Health Science Promotion Project of Beijing (TG-2015-003), the Scientific Research Foundation for Capital Medicine Development (2016-1-4082), and Beijing Key Laboratory for Hematopoietic Stem Cell Transplantation.


[1] F. Aversa, A. Terenzi, A. Tabilio et al., "Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse," Journal of Clinical Oncology, vol. 23, no. 15, pp. 3447-3454, 2005.

[2] Y. J. Chang and X. J. Huang, "Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts," Current Opinion in Hematology, vol. 19, no. 6, pp. 454-461, 2012.

[3] Y. Reisner, D. Hagin, and M. F. Martelli, "Haploidentical hematopoietic transplantation: current status and future perspectives," Blood, vol. 118, no. 23, pp. 6006-6017, 2011.

[4] X. H. Zhang, S. Y. Zhou, R. Feng et al., "Increased prostacyclin levels inhibit the aggregation and activation of platelets via the PI3K-AKT pathway in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation," Thrombosis Research, vol. 139, pp. 1-9, 2016.

[5] X. H. Zhang, Q. M. Wang, J. M. Zhang et al., "Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT," Journal of Hematology & Oncology, vol. 8, no. 1, p. 116, 2015.

[6] R. Yamazaki, M. Kuwana, T. Mori et al., "Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover," Bone Marrow Transplantation, vol. 38, no. 5, pp. 377-384, 2006.

[7] R. S. Mehta, R. M. Saliba, J. Chen et al., "Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation," British Journal of Haematology, vol. 173, no. 3, pp. 444-455, 2016.

[8] Y. Kong, Y. Hu, X. H. Zhang et al., "Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation," Biology of Blood and Marrow Transplantation, vol. 20, no. 8, pp. 1190-1197, 2014.

[9] R. A. Nash, T. Gooley, C. Davis, and F. R. Appelbaum, "The problem of thrombocytopenia after hematopoietic stem cell transplantation," The Oncologist, vol. 1, no. 6, pp. 371-380, 1996.

[10] S. O. Ciurea, P. F. Thall, X. Wang et al., "Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation," Blood, vol. 118, no. 22, pp. 5957-5964, 2011.

[11] C. Cutler, H. T. Kim, L. Sun et al., "Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation," Blood, vol. 118, no. 25, pp. 6691-6697, 2011.

[12] A. Ruggeri, V. Rocha, E. Masson et al., "Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Societe Francophone d'Histocompatibilite et d'Immunogenetique (SFHI) and Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) analysis," Haematologica, vol. 98, no. 7, pp. 1154-1160, 2013.

[13] S. Yoshihara, E. Maruya, K. Taniguchi et al., "Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT," Bone Marrow Transplantation, vol. 47, no. 4, pp. 508-515, 2012.

[14] S. O. Ciurea, M. de Lima, P. Cano et al., "High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation," Transplantation, vol. 88, no. 8, pp. 1019-1024, 2009.

[15] Y. J. Chang, X. Y. Zhao, L. P. Xu et al., "Donor-specific antihuman leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets," Journal of Hematology & Oncology, vol. 8, no. 1, p. 84, 2015.

[16] Y. Wang, H. X. Fu, D. H. Liu et al., "Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial," Bone Marrow Transplantation, vol. 49, no. 3, pp. 426-433, 2014.

[17] Y. Wang, D. H. Liu, K. Y. Liu et al., "Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center," Cancer, vol. 119, no. 5, pp. 978-985, 2013.

[18] X. Y. Qin, G. X. Li, Y. Z. Qin et al., "Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT," Bone Marrow Transplantation, vol. 49, no. 10, pp. 1269-1277, 2014.

[19] S. Morin-Zorman, P. Loiseau, J. L. Taupin, and S. Caillat-Zucman, "Donor-specific anti-HLA antibodies in allogeneic hematopoietic stem cell transplantation," Frontiers in Immunology, vol. 7, p. 307, 2016.

[20] Y. J. Chang, L. Luznik, E. J. Fuchs, and X. J. Huang, "How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?" Journal of Hematology & Oncology, vol. 9, no. 1, p. 35, 2016.

[21] Y. Wang, Y. J. Chang, L. P. Xu et al., "Who is the best donor for a related HLA haplotype-mismatched transplant?" Blood, vol. 124, no. 6, pp. 843-850, 2014.

[22] S. Spellman, R. Bray, S. Rosen-Bronson et al., "The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure," Blood, vol. 115, no. 13, pp. 2704-2708, 2010.

[23] A. J. Barge, G. Johnson, R. Witherspoon, and B. Torok-Storb, "Antibody-mediated marrow failure after allogeneic bone marrow transplantation," Blood, vol. 74, no. 5, pp. 1477-1480, 1989.

[24] Y. Kong, Y. Hu, X. H. Zhang et al., "Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation," Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, vol. 20, no. 8, pp. 1190-1197, 2014.

[25] X. H. Zhang, G. X. Wang, H. H. Zhu et al., "Recruitment of CD8(+) T cells into bone marrow might explain the suppression of megakaryocyte apoptosis through high expression of CX3CR1(+) in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation," Annals of Hematology, vol. 94, no. 10, pp. 1689-1698, 2015.

[26] C. G. Kanakry, E. J. Fuchs, and L. Luznik, "Modern approaches to HLA-haploidentical blood or marrow transplantation," Nature Reviews. Clinical Oncology, vol. 13, no. 1, pp. 10-24, 2016.

Xiaosu Zhao, (1,2) Xiangyu Zhao, (1,2) Mingrui Huo, (1) Qiaozhen Fan, (1) Xuying Pei, (1) Yu Wang, (1,2) Xiaohui Zhang, (1) Lanping Xu, (1) Xiaojun Huang, (1,2,3) Kaiyan Liu, (1) and Yingjun Chang (1,2)

(1) Peking University People's Hospital and Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 South Street of Xizhimen, Xicheng District, Beijing 100044, China

(2) Collaborative Innovation Center of Hematology, Peking University, Beijing, China

(3) Peking-Tsinghua Center for Life Sciences, Beijing 100871, China

Correspondence should be addressed to Yingjun Chang;

Received 11 October 2016; Revised 22 December 2016; Accepted 20 March 2017; Published 16 April 2017

Academic Editor: Mepur H. Ravindranath

Caption: Figure 1: PT and transplant outcomes after haploidentical transplantation. (a) Cumulative incidence of relapse (CIR) and (b) TRM. (c) Disease-free survival. (d) Overall survival.
Table 1: Patient and donor characteristics.

Characteristics                                        n = 394

Median age (range), years                             26 (2-58)
Male sex, n (%)                                      231 (58.6%)
  AML, n (%)                                         160 (40.6%)
  ALL, n (%)                                         133 (33.8%)
  CML, n (%)                                          22 (5.6%)
  MDS, n (%)                                         41 (10.4%)
  Others, n (%)                                       38 (9.6%)
Disease status, SR (%)                               301 (76.4%)
Conditioning regimen
  MA, n (%)                                          394 (100%)
Number of HLA-A, B, DR mismatched, n (%)
  0                                                   3 (0.8%)
  1                                                   22 (5.6%)
  2                                                  87 (22.1%)
  3                                                  282 (71.6%)
Donor-recipient sex match, n (%)
  Male-male                                          149 (37.8%)
  Male-female                                        102 (25.9%)
  Female-male                                        84 (21.3%)
  Female-female                                       59 (15%)
Donor-recipient relationship, n (%)
  Father-child                                       150 (38.1%)
  Mother-child                                       57 (14.5%)
  Sibling-sibling                                    117 (29.%)
  Child-parent                                       58 (14.7%)
  Others                                              12 (3.0%)
ABO matched, n (%)
  Matched                                            224 (56.9%)
  Major mismatched                                   74 (18.8%)
  Minor mismatched                                    22 (5.6%)
  Bidirect mismatched                                74 (18.8%)
Cell compositions in allografts, median (range)
  Infused nuclear cells, [10.sup.8]/kg            8.23 (1.78-23.69)
  Infused [CD34.sup.+] cells, [10.sup.6]/kg       2.61 (0.39-16.82)
  Infused lymphocytes, [10.sup.8]/kg              2.93 (0.16-9.49)
  Infused [CD3.sup.+] cells, [10.sup.8]/kg         2.0 (0.1-5.93)
  Infused [CD4.sup.+] cells, [10.sup.8]/kg         1.1 (0.15-3.94)
  Infused [CD8.sup.+] cells, [10.sup.8]/kg        0.69 (0.05-2.47)
  Infused [CD14.sup.+] cells, [10.sup.8]/kg       1.48 (0.19-6.13)
  Grade 0-I aGVHD                                    259 (65.7%)
  Grade II-IV aGVHD                                  135 (34.3%)
  No cGVHD                                           266 (67.5%)
  cGVHD                                              128 (32.5%)

Table 2: The HLA-antibodies and DSA in different statuses
of engraftment.

                         Good engraftment        PT

With positive anti-HLA    27/295 (9.2%)     6/32 (18.8%)
  antibody (n, %)
Median DSA MFI                 3096             9374
Range of DSA MFI            504-12969        1403-18950

                              PGF            GR

With positive anti-HLA   12/39 (30.8%)   4/4 (100%)
  antibody (n, %)
Median DSA MFI               4843          17214
Range of DSA MFI           600-11736     3793-19948

Table 3: Patient characteristics in groups with and without PT.

                                         PT       Without PT   P value

N                                        32          362
Patient age, median (range)           36 (3-54)   26 (2-58)     0.020
Patient sex, male, n (%)              17 (53.1)   214 (59.1)    0.320
Diagnosis, n (%)                                                0.510
  AML                                 13 (40.6)   147 (40.6)
  ALL                                 14 (43.8)   119 (32.9)
  CML                                  1 (3.1)     21 (5.8)
  MDS                                  3 (9.4)    38 (10.5)
  Others                               1 (3.1)    37 (10.2)
Disease risk, n (%)
  SR                                  22 (68.8)   279 (77.1)    0.288
  HR                                  10 (31.3)   83 (22.9)
HLA incompatibility, n (%)                                      0.533
  0 locus                                 0        3 (0.8)
  1 locus                              2 (6.3)     20 (5.5)
  2 loci                              4 (12.5)    83 (22.9)
  3 loci                              26 (81.3)   256 (70.7)
Donor-patient relation, n (%)                                   0.260
  Sibling donor                       9 (28.1)    108 (29.8)
  Father donor                        4 (12.5)    53 (14.6)
  Mother donor                        9 (28.1)    141 (39.0)
  Children donor                      9 (28.1)    49 (13.5)
  Others                               1 (3.1)     11 (3.0)
Donor-patient sex match, number (%)                             0.722
  Male to male                        11 (34.4)   138 (38.1)
  Male to female                      11 (34.4)   91 (25.1)
  Female to male                      6 (18.8)    78 (21.5)
  Female to female                    4 (12.5)    55 (15.2)
ABO matched, n (%)                                              0.213
  Matched                             15 (46.9)   209 (57.7)
  Major mismatched                    8 (25.0)    66 (18.2)
  Minor mismatched                    5 (15.6)    69 (19.1)
  Bidirect mismatched                 4 (12.5)     18 (5.0)
Cell compositions in allografts,
n (%)
Infused nuclear cells [greater than   15 (46.9)   181 (50.0)    0.735
or equal to] median

Infused [CD34.sup.+] cells [greater   11 (34.4)   187 (51.7)    0.061
than or equal to] median

Infused lymphocytes [greater than     13 (48.1)   160 (50.3)    0.829
or equal to] median

Infused [CD3.sup.+] cells [greater    14 (51.9)   160 (50.3)    0.878
than or equal to] median

Infused [CD4.sup.+] cells [greater    16 (59.3)   159 (50.0)    0.356
than or equal to] median

Infused [CD8.sup.+] cells [greater    16 (59.3)   157 (49.4)    0.324
than or equal to] median

Infused [CD14.sup.+] cells [greater   16 (59.3)   157 (49.4)    0.324
than or equal to] median

Grade II-IV aGVHD                     12 (44.4)   105 (33.0)    0.229
cGVHD                                 8 (25.0)    120 (33.2)    0.320
HLA antibody positive                 12 (37.5)   87 (24.0)     0.092
HLA-I antibody positive               6 (18.8)    57 (17.9)     0.579
HLA-II antibody positive              8 (25.0)    49 (13.5)     0.056
HLA-DP antibody positive               3 (9.4)     29 (8.0)     0.732
DSA positive                          6 (18.8)    39 (10.8)     0.174
MFI > 1000                            6 (18.6)     31 (8.6)     0.058
MFI > 2000                            4 (12.5)     27 (7.5)     0.310

AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia;
CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome; SR:
standard risk; HR: high risk; aGVHD: acute graft-versus-host
disease; cGVHD: chronic graft-versus-host disease; HLA-I/II: class
I/II HLA antibody; HLA-DP: class I and II HLA antibody double
positive; DSA: donor-specific antibody; DSA-DP: class I and II DSA
double positive; MFI: median fluorescent intensity. Bold means
variates included in the multivariate analysis since their P value
< 0.1 in the univariate analysis.

Table 4: Multivariate analysis of factors associated with transplant

                                         HR        95% CI       P value

Prolonged isolated
Infused CD34+ cells [greater than       0.481    0.232-1.001     0.050
  or equal to] median

  MFI [greater than or equal to] 1000   3.262    1.339-7.946     0.009

  Disease status                        1.753   (0.985-3.118)    0.056
  Infused CD4+ cells [greater than      1.899   (1.079-3.340)    0.026
  or equal to] median

  MFI [greater than or equal to] 1000   2.320   (1.169-4.426)    0.044

  Disease status                        3.882   (2.103-7.166)   <0.001
  HLA-DP                                2.552   (1.139-5.742)   0.0230

  Disease status                        2.667   (1.761-4.038)   <0.001
  cGVHD                                 0.622   (0.423-0.916)   <0.016

  Disease status                        2.504   (1.643-3.817)   <0.001
  cGVHD                                 0.612   (0.413-0.908)    0.015
  MFI [greater than or equal to] 1000   1.220   (0.998-2.138)    0.082
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Zhao, Xiaosu; Zhao, Xiangyu; Huo, Mingrui; Fan, Qiaozhen; Pei, Xuying; Wang, Yu; Zhang, Xiaohui; Xu,
Publication:Journal of Immunology Research
Article Type:Report
Geographic Code:9CHIN
Date:Jan 1, 2017
Previous Article:Diagnostic and Research Aspects of Small Intestinal Disaccharidases in Coeliac Disease.
Next Article:The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by...

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters